Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
5 ETF Investment Ideas for 2017
by Neena Mishra
We have highlighted some ETF areas that are likely to shine in 2017.
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
by Zacks Equity Research
Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
Company News for January 03, 2017
by Zacks Equity Research
Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.
Achillion Receives $15M from J&J for HCV Study Enrolment
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?
by Zacks Equity Research
In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).
J&J Files for FDA Approval of Simponi Aria Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ), Janssen submitted two sBLAs in the U.S. seeking approval of Simponi Aria for the treatment of psoriatic arthritis and ankylosing spondylitis.
Big Pharma Face Off: Is Merck More Attractive than J&J?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks
Company News for December 15, 2016
by Zacks Equity Research
Companies In The News are: ABM,JNJ,ALIOF,HTZ,VRX
Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.
J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
by Zacks Equity Research
On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.
Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy
by Zacks Equity Research
Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.
3 Stocks That Propelled the Dow to a Fresh All-Time High
by Swarup Gupta
Analyzing the reasons behind these gains could help us in ascertaining whether they are sustainable.